Ladarixin, an inhibitor of the interleukin‐8 receptors CXCR1 and CXCR2, in new‐onset type 1 diabetes: A multicentre, randomized, double‐blind, placebo‐controlled trial

AIM: To evaluate the ability of ladarixin (LDX, 400 mg twice‐daily for three cycles of 14 days on/14 days off), an inhibitor of the CXCR1/2 chemokine receptors, to maintain C‐peptide production in adult patients with newly diagnosed type 1 diabetes. MATERIALS AND METHODS: A double‐blind, randomized...

Descripción completa

Detalles Bibliográficos
Autores principales: Piemonti, Lorenzo, Keymeulen, Bart, Gillard, Pieter, Linn, Thomas, Bosi, Emanuele, Rose, Ludger, Pozzilli, Paolo, Giorgino, Francesco, Cossu, Efisio, Daffonchio, Luisa, Goisis, Giovanni, Ruffini, Pier Adelchi, Maurizi, Anna Rita, Mantelli, Flavio, Allegretti, Marcello
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9540558/
https://www.ncbi.nlm.nih.gov/pubmed/35589610
http://dx.doi.org/10.1111/dom.14770

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9540558/
https://www.ncbi.nlm.nih.gov/pubmed/35589610
http://dx.doi.org/10.1111/dom.14770

Ejemplares similares